NAChR Dysfunction As a Common Substrate for Schizophrenia and Comorbid Nicotine Addiction: Current Trends and Perspectives

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2016 Jan 25

PMID 26803692

Citations 44

Authors

Vinay Parikh

Munir Gunes Kutlu

Thomas J Gould

Affiliations

Soon will be listed here.

Abstract

Introduction: The prevalence of tobacco use in the population with schizophrenia is enormously high. Moreover, nicotine dependence is found to be associated with symptom severity and poor outcome in patients with schizophrenia. The neurobiological mechanisms that explain schizophrenia-nicotine dependence comorbidity are not known. This study systematically reviews the evidence highlighting the contribution of nicotinic acetylcholine receptors (nAChRs) to nicotine abuse in schizophrenia.

Methods: Electronic data bases (Medline, Google Scholar, and Web of Science) were searched using the selected key words that match the aims set forth for this review. A total of 276 articles were used for the qualitative synthesis of this review.

Results: Substantial evidence from preclinical and clinical studies indicated that dysregulation of α7 and β2-subunit containing nAChRs account for the cognitive and affective symptoms of schizophrenia and nicotine use may represent a strategy to remediate these symptoms. Additionally, recent meta-analyses proposed that early tobacco use may itself increase the risk of developing schizophrenia. Genetic studies demonstrating that nAChR dysfunction that may act as a shared vulnerability factor for comorbid tobacco dependence and schizophrenia were found to support this view. The development of nAChR modulators was considered an effective therapeutic strategy to ameliorate psychiatric symptoms and to promote smoking cessation in schizophrenia patients.

Conclusions: The relationship between schizophrenia and smoking is complex. While the debate for the self-medication versus addiction vulnerability hypothesis continues, it is widely accepted that a dysfunction in the central nAChRs represent a common substrate for various symptoms of schizophrenia and comorbid nicotine dependence.

Citing Articles

Distinct Chrna5 mutations link excessive alcohol use to types I/II vulnerability profiles and IPN GABAergic neurons.

Tochon L, Henkous N, Besson M, Maskos U, David V Transl Psychiatry. 2024; 14(1):461.

PMID: 39505853 PMC: 11541707. DOI: 10.1038/s41398-024-03164-8.

Evaluating the Impact of Motivational Enhancement Therapy on Tobacco Cessation in Schizophrenia: A Comprehensive Review.

Asmita , Patil P, Sahu N Cureus. 2024; 16(9):e70046.

PMID: 39469376 PMC: 11516333. DOI: 10.7759/cureus.70046.

Upregulation of cholinergic modulators Lypd6 and Lypd6b associated with autism drives anxiety and cognitive decline.

Isaev A, Bychkov M, Kulbatskii D, Andreev-Andrievskiy A, Mashkin M, Shulepko M Cell Death Discov. 2024; 10(1):444.

PMID: 39433742 PMC: 11494011. DOI: 10.1038/s41420-024-02211-z.

Nicotine's Effects on Schizophrenia-like Symptoms in a Mice Model: Time Matters.

Dutra-Tavares A, Couto L, Souza T, Bandeira-Martins A, Silva J, Filgueiras C Brain Sci. 2024; 14(9).

PMID: 39335351 PMC: 11430416. DOI: 10.3390/brainsci14090855.

Impact of Serine Racemase Deletion on Nicotine Discrimination.

Yu I, Coyle J, Desai R Nicotine Tob Res. 2024; 26(12):1744-1748.

PMID: 38919117 PMC: 11582001. DOI: 10.1093/ntr/ntae156.

References

Kim H, Flanagin B, Qin C, Macdonald R, Stitzel J . The mouse Chrna4 A529T polymorphism alters the ratio of high to low affinity alpha 4 beta 2 nAChRs. Neuropharmacology. 2003; 45(3):345-54. DOI: 10.1016/s0028-3908(03)00167-9. View

Gonzalez-Burgos G, Lewis D . GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008; 34(5):944-61. PMC: 2518635. DOI: 10.1093/schbul/sbn070. View

Tietje K, Anderson D, Bitner R, Blomme E, Brackemeyer P, Briggs C . Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther. 2008; 14(1):65-82. PMC: 6494002. DOI: 10.1111/j.1527-3458.2008.00037.x. View

Terry Jr A, Gearhart D, Mahadik S, Warsi S, Davis L, Waller J . Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors. Neuroscience. 2005; 136(2):519-29. DOI: 10.1016/j.neuroscience.2005.08.006. View

Lieberman J, Dunbar G, Segreti A, Girgis R, Seoane F, Beaver J . A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013; 38(6):968-75. PMC: 3629385. DOI: 10.1038/npp.2012.259. View

Lijffijt M, Lane S, Meier S, Boutros N, Burroughs S, Steinberg J . P50, N100, and P200 sensory gating: relationships with behavioral inhibition, attention, and working memory. Psychophysiology. 2009; 46(5):1059-68. PMC: 2821570. DOI: 10.1111/j.1469-8986.2009.00845.x. View

Wing V, Wass C, Bacher I, Rabin R, George T . Varenicline modulates spatial working memory deficits in smokers with schizophrenia. Schizophr Res. 2013; 149(1-3):190-1. DOI: 10.1016/j.schres.2013.06.032. View

Olincy A, Young D, Freedman R . Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997; 42(1):1-5. DOI: 10.1016/S0006-3223(96)00302-2. View

Wing V, Wass C, Soh D, George T . A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci. 2011; 1248:89-106. DOI: 10.1111/j.1749-6632.2011.06261.x. View

10.

Guillem K, Bloem B, Poorthuis R, Loos M, Smit A, Maskos U . Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention. Science. 2011; 333(6044):888-91. DOI: 10.1126/science.1207079. View

11.

Spinella M . Correlations between orbitofrontal dysfunction and tobacco smoking. Addict Biol. 2003; 7(4):381-4. DOI: 10.1080/1355621021000005964. View

12.

Audrain-McGovern J, Rodriguez D, Epstein L, Cuevas J, Rodgers K, Wileyto E . Does delay discounting play an etiological role in smoking or is it a consequence of smoking?. Drug Alcohol Depend. 2009; 103(3):99-106. PMC: 2743449. DOI: 10.1016/j.drugalcdep.2008.12.019. View

13.

Kelley R, DasMahapatra P, Wang J, Chen W, Srinivasan S, Fernandez C . Prevalence of atherosclerotic plaque in young and middle-aged asymptomatic individuals: the Bogalusa heart study. South Med J. 2011; 104(12):803-8. DOI: 10.1097/SMJ.0b013e318236c35c. View

14.

Tseng K, ODonnell P . Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci. 2004; 24(22):5131-9. PMC: 6729185. DOI: 10.1523/JNEUROSCI.1021-04.2004. View

15.

Karadsheh M, Shah M, Tang X, Macdonald R, Stitzel J . Functional characterization of mouse alpha4beta2 nicotinic acetylcholine receptors stably expressed in HEK293T cells. J Neurochem. 2004; 91(5):1138-50. DOI: 10.1111/j.1471-4159.2004.02801.x. View

16.

Sacco K, Termine A, Seyal A, Dudas M, Vessicchio J, Krishnan-Sarin S . Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry. 2005; 62(6):649-59. DOI: 10.1001/archpsyc.62.6.649. View

17.

Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K . Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol. 2000; 393(1-3):237-42. DOI: 10.1016/s0014-2999(00)00035-2. View

18.

Lambe E, Picciotto M, Aghajanian G . Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology. 2003; 28(2):216-25. DOI: 10.1038/sj.npp.1300032. View

19.

Terry Jr A, Callahan P, Hernandez C . Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. Biochem Pharmacol. 2015; 97(4):388-398. PMC: 4752163. DOI: 10.1016/j.bcp.2015.07.027. View

20.

Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I . Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol. 2009; 78(7):703-11. DOI: 10.1016/j.bcp.2009.05.024. View